Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Maria Di BartolomeoMonica NigerGiuseppe TirinoAngelica PetrilloRosa BerenatoMaria Maddalena LaterzaFilippo PietrantonioFederica MoranoMaria AntistaSara LonardiLorenzo FornaroStefano TamberiElisa GiommoniAlberto ZaniboniLorenza RimassaGianluca TomaselloTeodoro SavaMassimiliano SpadaTiziana LatianoAlessandro BittoniAlessandro BertoliniIlaria ProserpioKatia Bruna BencardinoFrancesco GrazianoGiordano BerettaSalvatore GaldyJole VentrigliaSimone ScagnoliAndrea SpallanzaniRaffaella LongariniFerdinando De Vita

Published in: Targeted oncology (2019)

These "real-life" efficacy data on ramucirumab treatment are in line with previous randomized trials. Ramucirumab is well tolerated in daily clinical practice.

Keyphrases

clinical practice
electronic health record
big data
squamous cell carcinoma
small cell lung cancer
machine learning
mesenchymal stem cells